SBIR/STTR Research Award
Screen for Isoprenoid Production in M. tuberculosis
Award amount
$109,120Program and phase
SBIR · Phase IAward year
2003Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ECHELON BIOSCIENCES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- EDK8FFD24SC4
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): Isoprenoid compounds form a large ubiquitous class of natural products that fulfill a wide variety of essential cellular functions in all living organisms. In eukaryotes, isoprenoid compounds are synthesized by a mevalonate (MVA) dependent pathway. However, in many bacteria, these compounds are synthesized by an alternative, MVA-independent route whose first committed intermediate is 2-methylerythritol 4-phosphate (MEP). Both pathways converge at isopentenyl diphosphate (IPP) and subsequent steps are similar in all organisms. Since the MEP pathway is absent in mammals, it is considered an attractive target for the development of novel antibiotics. The pathogen, M. tuberculosis belongs to the MEP pathway class of organisms. The applicants will prepare a transgenic bacterial E. coli host cell whose genome contains disruptions in a first endogenous gene in the MEP pathway and a second endogenous gene which is located downstream of the first gene in the MEP pathway. A transgene from M. tuberculosis that functionally replaces the disrupted downstream gene will be cloned into the cell. The growth of the host cell in the presence of test agent is then compared to a control culture to determine the activity of the test agent. Where the test agent renders the bacterial host cell nonviable on media containing a chemical supplement to relieve the 1-deoxy-D-xylulose-5-phosphate (DXP) block and viable on the media containing MVA indicates that the test agent has the potential to be an effective antibacterial against M. tuberculosis.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Innovative Point-of-Care Solutions for Long-term Alcohol Biomarkers
- Optimized Platforms for Proper Glycosylation and Sialylation of Recombinant Human Butyrylcholinesterase (rBChE)
- Accessible And Robust Tools for Glycosaminoglycan Profiling
- Transgenic Black Soldier Flies for Sustainable, Improved Nutrition
- Transgenic black soldier flies for sustainable, improved nutrition